Skip to main content
Erschienen in: CNS Drugs 1/2006

01.01.2006 | Therapy In Practice

Polytherapy in Bipolar Disorder

verfasst von: Daniel Lin, Hiram Mok, Lakshmi N. Yatham

Erschienen in: CNS Drugs | Ausgabe 1/2006

Einloggen, um Zugang zu erhalten

Abstract

Bipolar disorder is a life-long condition that is associated with frequent recurrence/relapse of symptoms. Although putative mood stabilisers, such as lithium, are considered to improve the natural course of bipolar disorder, complete long-term remission is rarely achieved. In order to effectively control mood symptoms and to reduce relapse, clinicians often use polypharmacy to treat patients with bipolar disorder. In this article, we examine the recent literature on treatment strategies in bipolar disorder to determine if combination treatments provide additional benefit over monotherapy for the management of various phases of bipolar disorder.
The evidence suggests that for acute mania a combination of lithium or valproate and an atypical antipsychotic is the most effective approach, with approximately 20% more patients responding to the combination than to monotherapy with any antimanic agent. Few studies have examined the use of combination therapy in comparison to monotherapy for bipolar depression. The limited evidence suggests that lithium plus an antidepressant appears to be more effective than lithium alone in those with lower serum lithium concentrations. Similarly, the combination of olanzapine plus fluoxetine is more effective than olanzapine alone. There is consensus that antidepressant monotherapy is not appropriate because of concerns of a manic switch, but monotherapy with lithium or lamotrigine may be adequate for mild to moderate bipolar depression.
For maintenance treatment, commonly used agents, such as lithium, valproate or olanzapine appear to be most effective in preventing manic relapses, whereas lamotrigine is more effective in preventing depressive relapses. As a result of these findings, it makes intuitive sense to combine lamotrigine with lithium, valproate or an atypical antipsychotic to achieve better mood stability. However, the efficacy and safety of such combinations have not been systematically compared with monotherapy. Preliminary studies suggest that lithium plus valproate may be more effective than lithium alone in preventing affective relapses. Similarly, the combination of lithium or valproate plus olanzapine seems to be more effective than monotherapy with a mood stabiliser in preventing manic episodes.
Literatur
1.
Zurück zum Zitat Goldberg JF, Harrow M, Grossman LS. Course and outcome in bipolar affective disorder: a longitudinal follow-up study. Am J Psychiatry 1995; 152(3): 379–84PubMed Goldberg JF, Harrow M, Grossman LS. Course and outcome in bipolar affective disorder: a longitudinal follow-up study. Am J Psychiatry 1995; 152(3): 379–84PubMed
2.
Zurück zum Zitat Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 2003; 64(2): 161–74PubMedCrossRef Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 2003; 64(2): 161–74PubMedCrossRef
3.
Zurück zum Zitat Dalton EJ, Cate-Carter TD, Mundo E, et al. Suicide risk in bipolar patients: the role of co-morbid substance use disorders. Bipolar Disord 2003; 5(1): 58–61PubMedCrossRef Dalton EJ, Cate-Carter TD, Mundo E, et al. Suicide risk in bipolar patients: the role of co-morbid substance use disorders. Bipolar Disord 2003; 5(1): 58–61PubMedCrossRef
4.
Zurück zum Zitat Tondo L, Isacsson G, Baldessarini R. Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs 2003; 17(7): 491–511PubMedCrossRef Tondo L, Isacsson G, Baldessarini R. Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs 2003; 17(7): 491–511PubMedCrossRef
5.
Zurück zum Zitat Sachs GS, Rush AJ. Response, remission, and recovery in bipolar disorders: what are the realistic treatment goals? J Clin Psychiatry 2003; 64Suppl. 6: 18–22PubMed Sachs GS, Rush AJ. Response, remission, and recovery in bipolar disorders: what are the realistic treatment goals? J Clin Psychiatry 2003; 64Suppl. 6: 18–22PubMed
6.
Zurück zum Zitat Post RM, Denicoff KD, Leverich GS, et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry 2003; 64(6): 680–90PubMedCrossRef Post RM, Denicoff KD, Leverich GS, et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry 2003; 64(6): 680–90PubMedCrossRef
7.
Zurück zum Zitat Kupfer DJ, Frank E, Grochocinski VJ, et al. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry 2002; 63(2): 120–5PubMedCrossRef Kupfer DJ, Frank E, Grochocinski VJ, et al. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry 2002; 63(2): 120–5PubMedCrossRef
8.
Zurück zum Zitat Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000; 61(1): 9–15PubMedCrossRef Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000; 61(1): 9–15PubMedCrossRef
9.
Zurück zum Zitat Freeman MP, Stoll AL. Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry 1998; 155(1): 12–21PubMed Freeman MP, Stoll AL. Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry 1998; 155(1): 12–21PubMed
10.
Zurück zum Zitat Practice guidelines for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159 (4 Suppl.): 1-50 Practice guidelines for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159 (4 Suppl.): 1-50
11.
Zurück zum Zitat Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994; 271(12): 918–24 Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994; 271(12): 918–24
12.
Zurück zum Zitat McElroy SL, Keck PE, Stanton SP, et al. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 1996; 57(4): 142–6PubMed McElroy SL, Keck PE, Stanton SP, et al. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 1996; 57(4): 142–6PubMed
13.
Zurück zum Zitat Oluboka OJ, Bird DC, Kutcher S, et al. A pilot study of loading versus titration of valproate in the treatment of acute mania. Bipolar Disord 2002; 4(5): 341–5PubMedCrossRef Oluboka OJ, Bird DC, Kutcher S, et al. A pilot study of loading versus titration of valproate in the treatment of acute mania. Bipolar Disord 2002; 4(5): 341–5PubMedCrossRef
14.
Zurück zum Zitat Post RM, Frye MA, Denicoff KD, et al. Beyond lithium in the treatment of bipolar illness. Neuropsychopharmacology 1998; 19(3): 206–19PubMedCrossRef Post RM, Frye MA, Denicoff KD, et al. Beyond lithium in the treatment of bipolar illness. Neuropsychopharmacology 1998; 19(3): 206–19PubMedCrossRef
15.
Zurück zum Zitat Chou JC. Recent advances in treatment of acute mania. J Clin Psychopharmacol 1991; 11(1): 3–21PubMed Chou JC. Recent advances in treatment of acute mania. J Clin Psychopharmacol 1991; 11(1): 3–21PubMed
16.
Zurück zum Zitat Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999; 35(1): 51–68PubMedCrossRef Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999; 35(1): 51–68PubMedCrossRef
17.
Zurück zum Zitat Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999; 156(5): 702–9 Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999; 156(5): 702–9
18.
Zurück zum Zitat Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry 2000; 57(9): 841–9CrossRef Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry 2000; 57(9): 841–9CrossRef
19.
Zurück zum Zitat Keck Jr PE, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003; 160(4): 741–8PubMedCrossRef Keck Jr PE, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003; 160(4): 741–8PubMedCrossRef
20.
Zurück zum Zitat Hirschfeld RM, Keck Jr PE, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004; 161(6): 1057–65PubMedCrossRef Hirschfeld RM, Keck Jr PE, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004; 161(6): 1057–65PubMedCrossRef
21.
Zurück zum Zitat Smulevich AB, Khanna S, Eerdekens M, et al. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol 2005; 15(1): 75–84PubMedCrossRef Smulevich AB, Khanna S, Eerdekens M, et al. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol 2005; 15(1): 75–84PubMedCrossRef
22.
Zurück zum Zitat Khanna S, Vieta E, Lyons B, et al. Risperidone in the treatment of acute bipolar mania: a double-blind, placebo-controlled study of 290 patients. Eur Neuropsychopharmacol 2003; 13: S314–5CrossRef Khanna S, Vieta E, Lyons B, et al. Risperidone in the treatment of acute bipolar mania: a double-blind, placebo-controlled study of 290 patients. Eur Neuropsychopharmacol 2003; 13: S314–5CrossRef
23.
Zurück zum Zitat McIntyre RS, Brecher M, Paulsson B. Quetiapine or haloperidol as monotherapy for bipolar mania: a 12-week, double blind, randomised, parallel group, placebo-controlled trial. Eur Neuropsychopharmacol 2005; 15(5): 573–85PubMedCrossRef McIntyre RS, Brecher M, Paulsson B. Quetiapine or haloperidol as monotherapy for bipolar mania: a 12-week, double blind, randomised, parallel group, placebo-controlled trial. Eur Neuropsychopharmacol 2005; 15(5): 573–85PubMedCrossRef
24.
Zurück zum Zitat Segal S, Riesenberg RA, Ice K, et al. Ziprasidone in mania: a 21-day randomized, double-blind, placebo controlled trial. Eur Neuropsychopharmacol 2003; 13: S345–6CrossRef Segal S, Riesenberg RA, Ice K, et al. Ziprasidone in mania: a 21-day randomized, double-blind, placebo controlled trial. Eur Neuropsychopharmacol 2003; 13: S345–6CrossRef
25.
Zurück zum Zitat Khanna S, Vieta E, Lyons B, et al. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry 2005; 187: 229–34PubMedCrossRef Khanna S, Vieta E, Lyons B, et al. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry 2005; 187: 229–34PubMedCrossRef
26.
Zurück zum Zitat Jones M, Huizar K. Quetiapine monotherapy for acute mania associated with bipolar disorder (STAMP 1 and STAMP 2) [abstract no. NR432]. 156th APA Annual Meeting; 2003 May 17–22; San Francisco (CA) Jones M, Huizar K. Quetiapine monotherapy for acute mania associated with bipolar disorder (STAMP 1 and STAMP 2) [abstract no. NR432]. 156th APA Annual Meeting; 2003 May 17–22; San Francisco (CA)
27.
Zurück zum Zitat Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. Int Clin Psychopharmacol 1999; 14(6): 339–43PubMedCrossRef Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. Int Clin Psychopharmacol 1999; 14(6): 339–43PubMedCrossRef
28.
Zurück zum Zitat Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 1998; 21(3): 176–80PubMed Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 1998; 21(3): 176–80PubMed
29.
Zurück zum Zitat Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003; 60(12): 1218–26PubMedCrossRef Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003; 60(12): 1218–26PubMedCrossRef
30.
Zurück zum Zitat Shi L, Namjoshi MA, Zhang F, et al. Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status. Int Clin Psychopharmacol 2002; 17(5): 227–37PubMedCrossRef Shi L, Namjoshi MA, Zhang F, et al. Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status. Int Clin Psychopharmacol 2002; 17(5): 227–37PubMedCrossRef
31.
Zurück zum Zitat Zajecka JM, Weisler R, Sachs G, et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002; 63(12): 1148–55PubMedCrossRef Zajecka JM, Weisler R, Sachs G, et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002; 63(12): 1148–55PubMedCrossRef
32.
Zurück zum Zitat Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002; 159(6): 1011–7PubMedCrossRef Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002; 159(6): 1011–7PubMedCrossRef
33.
Zurück zum Zitat Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005; 66(1): 111–21PubMedCrossRef Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005; 66(1): 111–21PubMedCrossRef
34.
Zurück zum Zitat Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002; 59(1): 62–9PubMedCrossRef Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002; 59(1): 62–9PubMedCrossRef
35.
Zurück zum Zitat Yatham LN, Grossman F, Augustyns I, et al. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry 2003; 182: 141–7 Yatham LN, Grossman F, Augustyns I, et al. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry 2003; 182: 141–7
36.
Zurück zum Zitat Sachs GS, Grossman F, Ghaemi SN, et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002; 159(7): 1146–54PubMedCrossRef Sachs GS, Grossman F, Ghaemi SN, et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002; 159(7): 1146–54PubMedCrossRef
37.
Zurück zum Zitat Delbello MP, Schwiers ML, Rosenberg HL, et al. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002; 41(10): 1216–23PubMedCrossRef Delbello MP, Schwiers ML, Rosenberg HL, et al. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002; 41(10): 1216–23PubMedCrossRef
38.
Zurück zum Zitat Sachs G, Chengappa KN, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004; 6(3): 213–23PubMedCrossRef Sachs G, Chengappa KN, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004; 6(3): 213–23PubMedCrossRef
39.
Zurück zum Zitat Sharma V, Persad E, Mazmanian D, et al. Treatment of rapid cycling bipolar disorder with combination therapy of valproate and lithium. Can J Psychiatry 1993; 38(2): 137–9PubMed Sharma V, Persad E, Mazmanian D, et al. Treatment of rapid cycling bipolar disorder with combination therapy of valproate and lithium. Can J Psychiatry 1993; 38(2): 137–9PubMed
40.
Zurück zum Zitat Reischies FM, Hartikainen J, Berghofer A. Initial lithium and valproate combination therapy in acute mania. Neuropsychobiology 2002; 46Suppl. 1: 22–7PubMedCrossRef Reischies FM, Hartikainen J, Berghofer A. Initial lithium and valproate combination therapy in acute mania. Neuropsychobiology 2002; 46Suppl. 1: 22–7PubMedCrossRef
41.
Zurück zum Zitat Granneman GR, Schneck DW, Cavanaugh JH, et al. Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium. J Clin Psychiatry 1996; 57(5): 204–6PubMed Granneman GR, Schneck DW, Cavanaugh JH, et al. Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium. J Clin Psychiatry 1996; 57(5): 204–6PubMed
42.
Zurück zum Zitat Small JG, Klapper MH, Marhenke JD, et al. Lithium combined with carbamazepine or haloperidol in the treatment of mania. Psychopharmacol Bull 1995; 31(2): 265–72PubMed Small JG, Klapper MH, Marhenke JD, et al. Lithium combined with carbamazepine or haloperidol in the treatment of mania. Psychopharmacol Bull 1995; 31(2): 265–72PubMed
43.
Zurück zum Zitat Tohen M, Castillo J, Pope Jr HG, et al. Concomitant use of valproate and carbamazepine in bipolar and schizoaffective disorders. J Clin Psychopharmacol 1994; 14(1): 67–70PubMedCrossRef Tohen M, Castillo J, Pope Jr HG, et al. Concomitant use of valproate and carbamazepine in bipolar and schizoaffective disorders. J Clin Psychopharmacol 1994; 14(1): 67–70PubMedCrossRef
44.
Zurück zum Zitat Schaff MR, Fawcett J, Zajecka JM. Divalproex sodium in the treatment of refractory affective disorders. J Clin Psychiatry 1993; 54(10): 380–4PubMed Schaff MR, Fawcett J, Zajecka JM. Divalproex sodium in the treatment of refractory affective disorders. J Clin Psychiatry 1993; 54(10): 380–4PubMed
45.
Zurück zum Zitat Ketter TA, Pazzaglia PJ, Post RM. Synergy of carbamazepine and valproic acid in affective illness: case report and review of the literature. J Clin Psychopharmacol 1992; 12(4): 276–81PubMedCrossRef Ketter TA, Pazzaglia PJ, Post RM. Synergy of carbamazepine and valproic acid in affective illness: case report and review of the literature. J Clin Psychopharmacol 1992; 12(4): 276–81PubMedCrossRef
46.
Zurück zum Zitat Keck Jr PE, McElroy SL, Nemeroff CB. Anticonvulsants in the treatment of bipolar disorder. J Neuropsychiatry Clin Neurosci 1992; 4(4): 395–405PubMed Keck Jr PE, McElroy SL, Nemeroff CB. Anticonvulsants in the treatment of bipolar disorder. J Neuropsychiatry Clin Neurosci 1992; 4(4): 395–405PubMed
47.
Zurück zum Zitat Bowden CL. Novel treatments for bipolar disorder. Expert Opin Investig Drugs 2001; 10(4): 661–71PubMedCrossRef Bowden CL. Novel treatments for bipolar disorder. Expert Opin Investig Drugs 2001; 10(4): 661–71PubMedCrossRef
48.
Zurück zum Zitat Chaudhry RP, Waters BG. Lithium and carbamazepine interaction: possible neurotoxicity. J Clin Psychiatry 1983; 44(1): 30–1PubMed Chaudhry RP, Waters BG. Lithium and carbamazepine interaction: possible neurotoxicity. J Clin Psychiatry 1983; 44(1): 30–1PubMed
49.
Zurück zum Zitat Shukla S, Godwin CD, Long LE, et al. Lithium-carbamazepine neurotoxicity and risk factors. Am J Psychiatry 1984; 141(12): 1604–6PubMed Shukla S, Godwin CD, Long LE, et al. Lithium-carbamazepine neurotoxicity and risk factors. Am J Psychiatry 1984; 141(12): 1604–6PubMed
50.
Zurück zum Zitat Onady AA, Calabrese JR. Carbamazepine auto- and heteroinduction complicating clinical care. J Clin Psychopharmacol 1989; 9(5): 387–8PubMed Onady AA, Calabrese JR. Carbamazepine auto- and heteroinduction complicating clinical care. J Clin Psychopharmacol 1989; 9(5): 387–8PubMed
51.
Zurück zum Zitat Sovner R. A clinically significant interaction between carbamazepine and valproic acid. J Clin Psychopharmacol 1988; 8(6): 448–9PubMedCrossRef Sovner R. A clinically significant interaction between carbamazepine and valproic acid. J Clin Psychopharmacol 1988; 8(6): 448–9PubMedCrossRef
52.
Zurück zum Zitat Srisurapanont M, Yatham LN, Zis AP. Treatment of acute bipolar depression: a review of the literature. Can J Psychiatry 1995; 40(9): 533–44PubMed Srisurapanont M, Yatham LN, Zis AP. Treatment of acute bipolar depression: a review of the literature. Can J Psychiatry 1995; 40(9): 533–44PubMed
53.
Zurück zum Zitat Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60(2): 79–88CrossRef Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60(2): 79–88CrossRef
54.
Zurück zum Zitat Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20(6): 607–14PubMedCrossRef Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20(6): 607–14PubMedCrossRef
55.
Zurück zum Zitat Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64(9): 1013–24PubMedCrossRef Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64(9): 1013–24PubMedCrossRef
56.
Zurück zum Zitat Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60(4): 392–400PubMedCrossRef Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60(4): 392–400PubMedCrossRef
57.
Zurück zum Zitat Burgess S, Geddes J, Hawton K, et al. Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev 2001; (3): CD003013 Burgess S, Geddes J, Hawton K, et al. Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev 2001; (3): CD003013
58.
Zurück zum Zitat Yatham LN, Calabrese JR, Kusumakar V. Bipolar depression: criteria for treatment selection, definition of refractoriness, and treatment options. Bipolar Disord 2003; 5(2): 85–97PubMedCrossRef Yatham LN, Calabrese JR, Kusumakar V. Bipolar depression: criteria for treatment selection, definition of refractoriness, and treatment options. Bipolar Disord 2003; 5(2): 85–97PubMedCrossRef
59.
Zurück zum Zitat Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994; 164(4): 549–50PubMedCrossRef Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994; 164(4): 549–50PubMedCrossRef
60.
Zurück zum Zitat Himmelhoch JM, Thase ME, Mallinger AG, et al. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148(7): 910–6PubMed Himmelhoch JM, Thase ME, Mallinger AG, et al. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148(7): 910–6PubMed
61.
Zurück zum Zitat Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60(11): 1079–88PubMedCrossRef Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60(11): 1079–88PubMedCrossRef
62.
Zurück zum Zitat Calabrese JR, Keck Jr PE, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005 Jul; 162(7): 1351–60PubMedCrossRef Calabrese JR, Keck Jr PE, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005 Jul; 162(7): 1351–60PubMedCrossRef
63.
Zurück zum Zitat Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001; 158(6): 906–12PubMedCrossRef Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001; 158(6): 906–12PubMedCrossRef
64.
Zurück zum Zitat Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994; 55(9): 391–3PubMed Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994; 55(9): 391–3PubMed
65.
Zurück zum Zitat Post RM, Altshuler LL, Frye MA, et al. Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disord 2001; 3(5): 259–65PubMedCrossRef Post RM, Altshuler LL, Frye MA, et al. Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disord 2001; 3(5): 259–65PubMedCrossRef
66.
Zurück zum Zitat Vieta E, Martinez-Aran A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002; 63(6): 508–12PubMedCrossRef Vieta E, Martinez-Aran A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002; 63(6): 508–12PubMedCrossRef
67.
Zurück zum Zitat Post RM, Altshuler LL, Leverich GS, et al. Higher swtich rates on venlafaxine than bupropion or sertraline in bipolar depression. Br J Psychiatry. In press Post RM, Altshuler LL, Leverich GS, et al. Higher swtich rates on venlafaxine than bupropion or sertraline in bipolar depression. Br J Psychiatry. In press
68.
Zurück zum Zitat Young LT, Joffe RT, Robb JC, et al. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 2000; 157(1): 124–6PubMed Young LT, Joffe RT, Robb JC, et al. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 2000; 157(1): 124–6PubMed
69.
Zurück zum Zitat Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry 2004; 65(12): 1715–9PubMedCrossRef Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry 2004; 65(12): 1715–9PubMedCrossRef
70.
Zurück zum Zitat Kusumakar V, Yatham LN. An open study of lamotrigine in refractory bipolar depression. Psychiatry Res 1997; 72(2): 145–8PubMedCrossRef Kusumakar V, Yatham LN. An open study of lamotrigine in refractory bipolar depression. Psychiatry Res 1997; 72(2): 145–8PubMedCrossRef
71.
Zurück zum Zitat Faught E, Morris G, Jacobson M, et al. Adding lamotrignine to valproate: incidence of rash and other adverse effects: Postmarketing Antiepileptic Drug Survey (PADS) group. Epilepsia 1999; 40(8): 1135–40PubMedCrossRef Faught E, Morris G, Jacobson M, et al. Adding lamotrignine to valproate: incidence of rash and other adverse effects: Postmarketing Antiepileptic Drug Survey (PADS) group. Epilepsia 1999; 40(8): 1135–40PubMedCrossRef
72.
Zurück zum Zitat Kramlinger KG, Post RM. The addition of lithium to carbamazepine: antidepressant efficacy in treatment-resistant depression. Arch Gen Psychiatry 1989; 46(9): 794–800PubMedCrossRef Kramlinger KG, Post RM. The addition of lithium to carbamazepine: antidepressant efficacy in treatment-resistant depression. Arch Gen Psychiatry 1989; 46(9): 794–800PubMedCrossRef
73.
Zurück zum Zitat Small JG. Anticonvulsants in affective disorders. Psychopharmacol Bull 1990; 26(1): 25–36PubMed Small JG. Anticonvulsants in affective disorders. Psychopharmacol Bull 1990; 26(1): 25–36PubMed
74.
Zurück zum Zitat Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry 1999; 60Suppl. 2: 77–84PubMed Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry 1999; 60Suppl. 2: 77–84PubMed
75.
Zurück zum Zitat Gelenberg AJ, Kane JM, Keller MB, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989; 321(22): 1489–93PubMedCrossRef Gelenberg AJ, Kane JM, Keller MB, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989; 321(22): 1489–93PubMedCrossRef
76.
Zurück zum Zitat Maj M, Pirozzi R, Magliano L, et al. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998; 155(1): 30–5PubMed Maj M, Pirozzi R, Magliano L, et al. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998; 155(1): 30–5PubMed
77.
Zurück zum Zitat Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57(5): 481–9 Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57(5): 481–9
78.
Zurück zum Zitat Macritchie KA, Geddes JR, Scott J, et al. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2001; (3): CD003196 Macritchie KA, Geddes JR, Scott J, et al. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2001; (3): CD003196
79.
Zurück zum Zitat Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000; 61(11): 841–50CrossRef Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000; 61(11): 841–50CrossRef
80.
Zurück zum Zitat Dardennes R, Even C, Bange F, et al. Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders: a meta-analysis. Br J Psychiatry 1995; 166(3): 378–81PubMedCrossRef Dardennes R, Even C, Bange F, et al. Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders: a meta-analysis. Br J Psychiatry 1995; 166(3): 378–81PubMedCrossRef
81.
Zurück zum Zitat Kleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology 2000; 42Suppl. 1: 2–10PubMedCrossRef Kleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology 2000; 42Suppl. 1: 2–10PubMedCrossRef
82.
Zurück zum Zitat Greil W, Ludwig-Mayerhofer W, Erazo N, et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders: a randomised study. J Affect Disord 1997; 43(2): 151–61PubMedCrossRef Greil W, Ludwig-Mayerhofer W, Erazo N, et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders: a randomised study. J Affect Disord 1997; 43(2): 151–61PubMedCrossRef
83.
Zurück zum Zitat Greil W, Kleindienst N. The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder. Int Clin Psychopharmacol 1999; 14(5): 277–81PubMed Greil W, Kleindienst N. The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder. Int Clin Psychopharmacol 1999; 14(5): 277–81PubMed
84.
Zurück zum Zitat Greil W, Kleindienst N. Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified. Int Clin Psychopharmacol 1999; 14(5): 283–5PubMed Greil W, Kleindienst N. Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified. Int Clin Psychopharmacol 1999; 14(5): 283–5PubMed
85.
Zurück zum Zitat Yatham LN. Acute and maintenance treatment of bipolar mania: the role of atypical antipsychotics. Bipolar Disord 2003; 5Suppl. 2: 7–19PubMedCrossRef Yatham LN. Acute and maintenance treatment of bipolar mania: the role of atypical antipsychotics. Bipolar Disord 2003; 5Suppl. 2: 7–19PubMedCrossRef
86.
Zurück zum Zitat Tohen MT, Bowden C, Calabrese J, et al. Olanzapine versus placebo for relapse prevention in bipolar disorder. Arch Gen Psychiatry. In press Tohen MT, Bowden C, Calabrese J, et al. Olanzapine versus placebo for relapse prevention in bipolar disorder. Arch Gen Psychiatry. In press
87.
Zurück zum Zitat Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005; 162(7): 1281–90PubMedCrossRef Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005; 162(7): 1281–90PubMedCrossRef
88.
Zurück zum Zitat American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
89.
Zurück zum Zitat Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004; 184: 337–45CrossRef Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004; 184: 337–45CrossRef
90.
Zurück zum Zitat Solomon DA, Ryan CE, Keitner GI, et al. A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder. J Clin Psychiatry 1997; 58(3): 95–9PubMedCrossRef Solomon DA, Ryan CE, Keitner GI, et al. A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder. J Clin Psychiatry 1997; 58(3): 95–9PubMedCrossRef
91.
Zurück zum Zitat Denicoff KD, Smith-Jackson EE, Disney ER, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58(11): 470–8PubMedCrossRef Denicoff KD, Smith-Jackson EE, Disney ER, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58(11): 470–8PubMedCrossRef
92.
Zurück zum Zitat Denicoff KD, Smith-Jackson EE, Bryan AL, et al. Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. Am J Psychiatry 1997; 154(10): 1456–8PubMed Denicoff KD, Smith-Jackson EE, Bryan AL, et al. Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. Am J Psychiatry 1997; 154(10): 1456–8PubMed
93.
Zurück zum Zitat Kusumakar V, Yatham LN, Haslam DR, et al. The foundations of effective management of bipolar disorder. Can J Psychiatry 1997; 42Suppl. 2: 69S-73S Kusumakar V, Yatham LN, Haslam DR, et al. The foundations of effective management of bipolar disorder. Can J Psychiatry 1997; 42Suppl. 2: 69S-73S
94.
Zurück zum Zitat Yatham LN, Kusumakar V, Parikh SV, et al. Bipolar depression: treatment options. Can J Psychiatry 1997; 42Suppl. 2: 87S–91SPubMed Yatham LN, Kusumakar V, Parikh SV, et al. Bipolar depression: treatment options. Can J Psychiatry 1997; 42Suppl. 2: 87S–91SPubMed
95.
Zurück zum Zitat Colom F, Vieta E, Martinez-Aran A, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003; 60(4): 402–7PubMedCrossRef Colom F, Vieta E, Martinez-Aran A, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003; 60(4): 402–7PubMedCrossRef
96.
Zurück zum Zitat Perry A, Tarder N, Morriss R, et al. Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. BMJ 1999; 318(7177): 149–53PubMedCrossRef Perry A, Tarder N, Morriss R, et al. Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. BMJ 1999; 318(7177): 149–53PubMedCrossRef
97.
Zurück zum Zitat Lam DH, Watkins ER, Hayward P, et al. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Arch Gen Psychiatry 2003; 60(2): 145–52PubMedCrossRef Lam DH, Watkins ER, Hayward P, et al. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Arch Gen Psychiatry 2003; 60(2): 145–52PubMedCrossRef
98.
Zurück zum Zitat Miklowitz DJ, Simoneau TL, George EL, et al. Family-focused treatment of bipolar disorder: 1-year effects of a psychoeducational program in conjunction with pharmacotherapy. Biol Psychiatry 2000; 48(6): 582-92PubMedCrossRef Miklowitz DJ, Simoneau TL, George EL, et al. Family-focused treatment of bipolar disorder: 1-year effects of a psychoeducational program in conjunction with pharmacotherapy. Biol Psychiatry 2000; 48(6): 582-92PubMedCrossRef
Metadaten
Titel
Polytherapy in Bipolar Disorder
verfasst von
Daniel Lin
Hiram Mok
Lakshmi N. Yatham
Publikationsdatum
01.01.2006
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 1/2006
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200620010-00003

Weitere Artikel der Ausgabe 1/2006

CNS Drugs 1/2006 Zur Ausgabe

Leading Article

Prion Diseases

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.